DeepMed Research

PIK3CA

Generic Name: PIK3CA

Drug Type: Biotech

Unique Ingredient Identifier: JQ83GG8LT2

Background: PIK3CA is under investigation in clinical trial NCT02957266 (Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy).

Clinical Trials

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2

Recruiting

Conditions: HER2-negative Breast Cancer
Advanced Breast Cancer
Breast Neoplasm
Breast Cancer
Hormone Receptor Positive Tumor

Interventions: Drug: PIK3CA inhibitor
Drug: AKT inhibitor
Drug: SHR-A1811
Drug: Carrelizumab
Drug: SHR-1167
Drug: Famitinib
Drug: Sorafenib
Drug: Everolimus
Drug: Fluzoparib
Drug: Aromatase Inhibitors or Fulvestrant
Drug: TPC
Drug: SHR-A1921
Drug: SHR-6209
Drug: Dalpiciclib
Drug: Apatinib
Drug: SHR-A2009
Drug: SHR-A2102
Drug: Goserelin
Drug: bevacizumab

First Posted Date: 2022-10-26

Last Posted Date: 2024-10-04

Lead Sponsor: Fudan University

Target Recruit Count: 620

Registration Number: NCT05594095

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy